These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 25559616

  • 1. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
    Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y, Kikkawa F, Takeshima N, Hatae M, Yokota H, Saito T, Yaegashi N, Kobayashi H, Baba T, Kodama S, Saito T, Sakuragi N, Sumi T, Kamura T, Yoshikawa H.
    Eur J Cancer; 2015 Feb; 51(3):340-51. PubMed ID: 25559616
    [Abstract] [Full Text] [Related]

  • 2. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS.
    Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
    [Abstract] [Full Text] [Related]

  • 3. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.
    de La Motte Rouge T, Pautier P, Duvillard P, Rey A, Morice P, Haie-Meder C, Kerbrat P, Culine S, Troalen F, Lhommé C.
    Ann Oncol; 2008 Aug; 19(8):1435-1441. PubMed ID: 18408223
    [Abstract] [Full Text] [Related]

  • 4. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors.
    Cicin I, Saip P, Guney N, Eralp Y, Ayan I, Kebudi R, Topuz E.
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810
    [Abstract] [Full Text] [Related]

  • 5. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
    Chen CA, Lin H, Weng CS, Wen KC, Lu CH, Chou HH, Huang YF, Kang CY, Ho CM, Yu MH, Chou CY.
    Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J, Yang W, Wu X.
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ, Zhang GN.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [Abstract] [Full Text] [Related]

  • 11. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, Gershenson DM.
    Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A, Fedyanin M, Kanagavel D, Fainstein I, Sergeev J, Polockij B, Matveev V, Zakharova T, Garin A, Tjulandin S.
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [Abstract] [Full Text] [Related]

  • 14. A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker SJ, Ledermann J, Berney DM, Shamash J, Banerjee S, Stoneham S, Lockley M.
    Eur J Cancer; 2019 May; 113():19-27. PubMed ID: 30954883
    [Abstract] [Full Text] [Related]

  • 15. Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases.
    Han JY, Nava-Ocampo AA, Kim TJ, Shim JU, Park CT.
    Reprod Toxicol; 2005 May; 19(4):557-61. PubMed ID: 15749271
    [Abstract] [Full Text] [Related]

  • 16. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A.
    Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
    [Abstract] [Full Text] [Related]

  • 17. Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study.
    Chu R, Liu P, Chen J, Cheng X, Li K, Che Y, Wang J, Li L, Zhang X, Yao S, Song L, Zhao Y, Huang C, Xue Y, Pan X, Li J, Chen Z, Jiang J, Kong B, Song K.
    J Gynecol Oncol; 2023 Mar; 34(2):e12. PubMed ID: 36890292
    [Abstract] [Full Text] [Related]

  • 18. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M, Miyake H, Hara I, Muramaki M, Takenaka A, Fujisawa M.
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of 129 patients with advanced and recurrent malignant ovarian germ cell tumor].
    Hong W, Zhang R, Liu L.
    Zhonghua Fu Chan Ke Za Zhi; 1998 Jan; 33(1):35-7. PubMed ID: 10682456
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.